|
시장보고서
상품코드
2054995
야간 빈뇨 시장 : 약제 클래스별, 투여 경로별, 제형별, 작용기전별, 처방 유형별, 연령층별, 성별, 유통 채널별, 최종사용자별, 지역별Nocturia Market, By Drug Class, By Route of Administration, By Dosage Form, By Mechanism of Action, By Prescription Type, By Age Group, By Gender, By Distribution Channel, By End User, By Geography |
||||||
야간 빈뇨 시장은 2026년에 47억 8,000만 달러로 추정되며, 2033년까지 83억 5,000만 달러에 이를 것으로 예상되고 있습니다. 또한 2026-2033년 CAGR 8.3%를 기록할 전망입니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도 : | 2025년 | 2026년 시장 규모 : | 47억 8,000만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 예측 기간(2026-2033년) CAGR : | 8.30% | 2033년 시장 규모 예측 : | 83억 5,000만 달러 |
세계 야간 빈뇨 시장은 비뇨기과 및 수면장애 치료제 분야의 광범위한 시장 동향에서 중요한 부분을 차지하며, 야간에 배뇨를 위해 잠에서 깨야 하는 특징을 가진 일반적인 증상을 다루는 시장입니다. 야간 빈뇨는 전 세계 수백만 명에게 영향을 미치고 있으며, 유병률은 나이가 들수록 현저히 증가하여 다양한 인구통계학적 집단의 남녀 모두에게 영향을 미치고 있습니다.
이러한 증상은 수면 패턴을 방해할 뿐만 아니라 삶의 질에도 큰 영향을 미치며, 주간 피로, 생산성 저하, 그리고 노년층의 낙상 위험 증가로 이어집니다. 이 시장에는 데스모프레신, 항콜린제, 알파 차단제 등의 약물 요법 외에도 행동 요법 및 의료기기 등의 비약물 요법을 포함한 다양한 치료법이 포함되어 있습니다. 의료계에서는 야간 빈뇨를 단순한 기저 질환의 증상이 아니라, 표적화된 치료적 개입이 필요한 독립적인 질환으로 인식하는 경향이 강해지고 있습니다. 이용 가능한 치료 옵션에 대한 환자와 의료 전문가들의 인식이 높아지는 데다, 전 세계적인 고령화와 당뇨병, 심부전, 전립선 비대증 등 관련 동반 질환의 유병률 증가가 맞물리면서 시장 확대와 치료 솔루션의 혁신이 지속적으로 추진되고 있습니다.
시장 역학
세계 야간 빈뇨 시장은 주로 몇 가지 강력한 요인에 의해 주도되고 있으며, 이러한 요인들이 결합되어 견실한 시장 성장과 확장 기회를 가져오고 있습니다. 가장 중요한 촉진요인은 급속히 진행되는 세계적 고령화입니다. 야간 빈뇨의 유병률은 나이가 들면서 크게 증가하여 65세 이상 인구의 최대 80%에 영향을 미치고 있으며, 치료적 개입이 필요한 환자층이 확대되고 있습니다. 의료 종사자와 환자들 사이에서 야간 빈뇨가 노화에 따른 피할 수 없는 현상이 아니라 치료 가능한 질환이라는 인식이 높아지면서, 진단율이 향상되고 치료를 받기 위한 행동으로 이어지고 있습니다. 게다가 야간 빈뇨의 발병에 기여하는 당뇨병, 심혈관 질환, 양성 전립선 비대증 등의 기저 질환 유병률 증가로 인해 잠재적 환자층이 더욱 확대되고 있습니다.
그러나 이 시장에는 뚜렷한 제약도 존재합니다. 환자의 인식 부족으로 인한 진단 및 치료의 미흡이 지적되며, 많은 사람들이 이러한 증상을 노화의 자연스러운 과정으로 받아들이고 의료적 개입을 요청하지 않는 실정입니다. 특히 야간 빈뇨의 병인이 복잡하고 종합적인 안전성 프로파일이 요구되기 때문에 신약 승인과 관련된 규제상의 과제가 혁신적인 치료법 시장 진입을 지연시킬 가능성이 있습니다. 높은 치료비와 특정 치료법에 대한 보험 적용 범위의 제한은 환자가 최적의 치료를 받을 기회를 제한할 수 있습니다. 이러한 과제가 있음에도 불구하고, 진단 도구의 기술적 진보로 인해 환자 군별 분류 및 맞춤형 치료 접근이 가능해짐에 따라, 큰 성장 기회가 존재합니다. 새로운 치료 표적 및 병용 요법의 개발은 큰 성장 잠재력을 지니고 있으며, 신흥 시장의 헬스케어 인프라 확충은 세계 시장 진출을 목표로 하는 기업들에게 새로운 수익원이 될 것입니다.
본 조사의 주요 특징
- 본 조사에서는 각 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장 성장 촉진요인, 시장 성장 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업들이 채택하는 경쟁 전략에 관한 중요한 인사이트를 제공합니다.
- 본 조사에서는 다음 매개변수를 바탕으로 전 세계 야간 빈뇨 시장의 주요 기업 프로파일을 작성했습니다. 기업 개요, 제품 포트폴리오, 주요 성과, 재무 실적 및 전략.
- 본 보고서의 인사이트를 활용함으로써, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 관해 정보에 기반한 의사결정을 내릴 수 있게 됩니다.
- 본 보고서는 야간 빈뇨 시장과 관련하여 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진출기업, 금융 애널리스트 등 해당 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 전 세계 야간 빈뇨 시장 분석에 활용되는 다양한 전략 매트릭스를 통해 의사결정을 보다 수월하게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 야간 빈뇨 시장 : 약제 클래스별, 2021년-2033년
제5장 세계의 야간 빈뇨 시장 : 투여 경로별, 2021년-2033년
제6장 세계의 야간 빈뇨 시장 : 제형별, 2021년-2033년
제7장 세계의 야간 빈뇨 시장 : 작용기전별, 2021년-2033년
제8장 세계의 야간 빈뇨 시장 : 처방 유형별, 2021년-2033년
제9장 세계의 야간 빈뇨 시장 : 연령층별, 2021년-2033년
제10장 세계의 야간 빈뇨 시장 : 성별, 2021년-2033년
제11장 세계의 야간 빈뇨 시장 : 유통 채널별, 2021년-2033년
제12장 세계의 야간 빈뇨 시장 : 최종사용자별, 2021년-2033년
제13장 세계의 야간 빈뇨 시장 : 지역별, 2021년-2033년
제14장 경쟁 구도
제15장 애널리스트의 제안
제16장 참고 문헌 및 조사 방법
LSH 26.06.19Nocturia Market is estimated to be valued at USD 4.78 Bn in 2026 and is expected to reach USD 8.35 Bn by 2033, growing at a compound annual growth rate (CAGR) of 8.3% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 4.78 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 8.30% | 2033 Value Projection: | USD 8.35 Bn |
The global nocturia market represents a critical segment within the broader urological and sleep disorder therapeutics landscape, addressing a prevalent medical condition characterized by the need to wake up during the night to urinate. Nocturia affects millions of individuals worldwide, with prevalence rates increasing significantly with age, impacting both men and women across various demographic groups.
This condition not only disrupts sleep patterns but also substantially affects quality of life, leading to daytime fatigue, reduced productivity, and increased risk of falls among elderly populations. The market encompasses various treatment modalities including pharmacological interventions such as desmopressin, anticholinergics, and alpha-blockers, alongside non-pharmacological approaches including behavioral modifications and medical devices. Healthcare providers increasingly recognize nocturia as a distinct medical condition requiring targeted therapeutic intervention rather than merely a symptom of underlying disorders. The growing awareness among patients and healthcare professionals about available treatment options, coupled with an aging global population and rising prevalence of associated comorbidities such as diabetes, heart failure, and benign prostatic hyperplasia, continues to drive market expansion and innovation in therapeutic solutions.
Market Dynamics
The global nocturia market is primarily driven by several compelling factors that collectively contribute to robust market growth and expansion opportunities. The most significant driver is the rapidly aging global population, as nocturia prevalence increases substantially with age, affecting up to 80% of individuals over 65 years, creating an expanding patient base requiring therapeutic intervention. Rising awareness among healthcare providers and patients about nocturia as a treatable medical condition rather than an inevitable aspect of aging has led to increased diagnosis rates and treatment seeking behavior. Additionally, the growing prevalence of underlying conditions such as diabetes mellitus, cardiovascular diseases, and benign prostatic hyperplasia, which contribute to nocturia development, further expands the potential patient population.
However, the market faces notable restraints including limited awareness among patients leading to underdiagnosis and undertreatment, with many individuals accepting the condition as a normal part of aging without seeking medical intervention. Regulatory challenges for new drug approvals, particularly given the complex etiology of nocturia and the need for comprehensive safety profiles, can delay market entry of innovative treatments. High treatment costs and limited insurance coverage for certain therapeutic options may restrict patient access to optimal care. Despite these challenges, significant opportunities exist through technological advancement in diagnostic tools enabling better patient stratification and personalized treatment approaches. The development of novel therapeutic targets and combination therapies presents substantial growth potential, while expanding healthcare infrastructure in emerging markets offers new revenue streams for market participants seeking global expansion.
Key Features of the Study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global nocturia market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Ferring Pharmaceuticals, Astellas Pharma Inc., Pfizer Inc., AbbVie Inc., Merck & Co., Inc., Sanofi S.A., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals Ltd., Avadel Pharmaceuticals plc, Sumitomo Pharma Co., Ltd., Urigen Pharmaceuticals Inc., Vantia Therapeutics Ltd., Viatris Inc., Allergan (an AbbVie company).
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global nocturia market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global nocturia market
Market Segmentation
- Drug Class Insights (Revenue, USD Bn, 2021 - 2033)
- Antidiuretic Agents (e.g., vasopressin analogs such as desmopressin)
- Alpha-1 Adrenergic Antagonists (e.g., tamsulosin, alfuzosin, silodosin, terazosin)
- Anticholinergic Agents (e.g., oxybutynin, tolterodine, solifenacin, darifenacin, trospium)
- Beta-3 Adrenergic Agonists (e.g., mirabegron, vibegron)
- Loop Diuretic Timing Therapies (e.g., furosemide administered in late-afternoon dosing)
- Combination Pharmacotherapies (e.g., mirabegron + solifenacin, alpha-blocker + anticholinergic)
- Route Of Administration Insights (Revenue, USD Bn, 2021 - 2033)
- Oral
- Intranasal
- Sublingual/orodispersible
- Parenteral and other systemic routes
- Dosage Form Insights (Revenue, USD Bn, 2021 - 2033)
- Immediate-release tablets or capsules
- Modified/extended-release oral formulations
- Orodispersible tablets or film
- Nasal sprays or drops
- Injectable formulations
- Mechanism Of Action Insights (Revenue, USD Bn, 2021 - 2033)
- Vasopressin Receptor Agonists
- Smooth Muscle Relaxants
- Muscarinic Receptor Blockers
- Beta-3 Receptor Stimulants
- Prostate-Targeted Relaxants
- Fluid-Regulation Modulators
- Prescription Type Insights (Revenue, USD Bn, 2021 - 2033)
- Prescription-Only Medicines (Rx)
- Over-the-Counter Options (OTC)
- Age Group Insights (Revenue, USD Bn, 2021 - 2033)
- Adult
- Geriatric
- Gender Insights (Revenue, USD Bn, 2021 - 2033)
- Male
- Female
- Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- End User Insights (Revenue, USD Bn, 2021 - 2033)
- Hospitals
- Specialty urology clinics
- Long-term care and nursing facilities
- Home-care and self-administration settings
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Ferring Pharmaceuticals
- Astellas Pharma Inc.
- Pfizer Inc.
- AbbVie Inc.
- Merck & Co., Inc.
- Sanofi S.A.
- GlaxoSmithKline plc
- Teva Pharmaceutical Industries Ltd.
- Glenmark Pharmaceuticals Ltd.
- Avadel Pharmaceuticals plc
- Sumitomo Pharma Co., Ltd.
- Urigen Pharmaceuticals Inc.
- Vantia Therapeutics Ltd.
- Viatris Inc.
- Allergan (an AbbVie company)
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Nocturia Market, By Drug Class
- Global Nocturia Market, By Route of Administration
- Global Nocturia Market, By Dosage Form
- Global Nocturia Market, By Mechanism of Action
- Global Nocturia Market, By Prescription Type
- Global Nocturia Market, By Age Group
- Global Nocturia Market, By Gender
- Global Nocturia Market, By Distribution Channel
- Global Nocturia Market, By End User
- Global Nocturia Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Nocturia Market, By Drug Class, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Antidiuretic Agents (e.g., vasopressin analogs such as desmopressin)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Alpha-1 Adrenergic Antagonists (e.g., tamsulosin, alfuzosin, silodosin, terazosin)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Anticholinergic Agents (e.g., oxybutynin, tolterodine, solifenacin, darifenacin, trospium)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Beta-3 Adrenergic Agonists (e.g., mirabegron, vibegron)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Loop Diuretic Timing Therapies (e.g., furosemide administered in late-afternoon dosing)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Combination Pharmacotherapies (e.g., mirabegron + solifenacin, alpha-blocker + anticholinergic)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
5. Global Nocturia Market, By Route of Administration, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Intranasal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Sublingual/orodispersible
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Parenteral and other systemic routes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
6. Global Nocturia Market, By Dosage Form, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Immediate-release tablets or capsules
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Modified/extended-release oral formulations
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Orodispersible tablets or film
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Nasal sprays or drops
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Injectable formulations
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
7. Global Nocturia Market, By Mechanism of Action, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Vasopressin Receptor Agonists
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Smooth Muscle Relaxants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Muscarinic Receptor Blockers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Beta-3 Receptor Stimulants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Prostate-Targeted Relaxants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Fluid-Regulation Modulators
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
8. Global Nocturia Market, By Prescription Type, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Prescription-Only Medicines (Rx)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Over-the-Counter Options (OTC)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
9. Global Nocturia Market, By Age Group, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Geriatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
10. Global Nocturia Market, By Gender, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Male
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Female
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
11. Global Nocturia Market, By Distribution Channel, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
12. Global Nocturia Market, By End User, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Specialty urology clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Long-term care and nursing facilities
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Home-care and self-administration settings
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
13. Global Nocturia Market, By Region, 2021 - 2033, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Mechanism of Action, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Prescription Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Mechanism of Action, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Prescription Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Mechanism of Action, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Prescription Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Mechanism of Action, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Prescription Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Mechanism of Action, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Prescription Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Mechanism of Action, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Prescription Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
14. Competitive Landscape
- Ferring Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Astellas Pharma Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi S.A.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GlaxoSmithKline plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Glenmark Pharmaceuticals Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Avadel Pharmaceuticals plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sumitomo Pharma Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Urigen Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Vantia Therapeutics Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Viatris Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Allergan (an AbbVie company)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
15. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
16. References and Research Methodology
- References
- Research Methodology
- About us
